{"name":"Eidos Therapeutics, a BridgeBio company","slug":"eidos-therapeutics-a-bridgebio-company","ticker":"","exchange":"","domain":"eidosabridgebiocompany.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Acoramidis (AG10)","genericName":"Acoramidis (AG10)","slug":"acoramidis-ag10","indication":"Transthyretin amyloid cardiomyopathy (ATTR-CM)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"AG10 oral tablet","genericName":"AG10 oral tablet","slug":"ag10-oral-tablet","indication":"Transthyretin cardiac amyloidosis (ATTR-CM), wild-type and hereditary forms","status":"phase_3"}]}],"pipeline":[{"name":"Acoramidis (AG10)","genericName":"Acoramidis (AG10)","slug":"acoramidis-ag10","phase":"phase_3","mechanism":"Acoramidis stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid disease.","indications":["Transthyretin amyloid cardiomyopathy (ATTR-CM)","Hereditary transthyretin amyloidosis (hATTR)"],"catalyst":""},{"name":"AG10 oral tablet","genericName":"AG10 oral tablet","slug":"ag10-oral-tablet","phase":"phase_3","mechanism":"AG10 stabilizes transthyretin (TTR) protein to prevent its misfolding and aggregation, which causes amyloid deposition in cardiac and neurological tissues.","indications":["Transthyretin cardiac amyloidosis (ATTR-CM), wild-type and hereditary forms"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBQalZObHhsOEF5ekh0VmhaRnk1MDZLY2VnaU5SeFdGVnU4bXZPV3pUdnZQNXhQbF9jWENCbTN0QlhIdUtLNUNhTVFFUzVNNklMUThBM21DbG5RODF2dXZPNzBhd2RDOE5EOWpIbDJKTnFaNlJ2NjN4NHU1NA?oc=5","date":"2025-03-27","type":"regulatory","source":"The Pharma Letter","summary":"BridgeBio’s Beyonttra approved in Japan - The Pharma Letter","headline":"BridgeBio’s Beyonttra approved in Japan","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQWRyT1JBR1hsMDRORXQxQnVkSVY4eElFVmFrSzliZFpKeUVubjhnSldHbHpMWkc5Wmo5VTh4c2Qyb3Q3TFp5dnkxeFVvZ2htRWo4c05fNWNDMDNSd3ZjZkZvTDQ4T2NyQUlCeTBuNjZrZGZ5Z19NcjJaTE9fY3dYMkl2aFN0Q2R3X2NJ?oc=5","date":"2025-02-28","type":"deal","source":"BioPharma Dive","summary":"BridgeBio oncology spinout to go public in blank-check merger - BioPharma Dive","headline":"BridgeBio oncology spinout to go public in blank-check merger","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxNaG80RC11c0tWWmttbTA3WklfaEktUkNkSlFNS0NBcXpLOVZ6NUxZVjA4cjBEdkpPYmtWeXR0WWtwYWZwZ1lQMV9zRTBCTmM2b2p2RjdEWks2Q0trb3doSlI3SE9lZTR1ck9WODA0R1UzQWJvb0tkWkp6dS03eDIwR2gxZ2tfWEM0OThENTN0X1NmNnRORXZvck1HRllBbVhFNTdldzdIMTQ1d005bEE?oc=5","date":"2024-03-03","type":"pipeline","source":"Reuters","summary":"Bayer purchases heart drug for up to $310 mln - Reuters","headline":"Bayer purchases heart drug for up to $310 mln","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPS3lkVVFZRXdma3BqOUlqV0VONG9HaXA4eDhNSXREQmszdEVEU0dhWnR1MTdFVkYwekZ3ajNRcTRkS0c1djVLemNlejFZYmZna3BMSHpEQ2dzOUQxWTdwOXdlTkw5a0tuNGN2OVp0dlB4OGpoWUNVNFVwV1V0WFdJMVQwWjMteV9VdnNuSVUxTnlxNXkyNWdIQ1I0bnQ?oc=5","date":"2023-08-09","type":"deal","source":"Bloomberg Law News","summary":"BridgeBio Wins Appeal Over Eidos Deal, Ending Pension Fund Suit - Bloomberg Law News","headline":"BridgeBio Wins Appeal Over Eidos Deal, Ending Pension Fund Suit","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5gFBVV95cUxOS0dSWUpMVEE5U2pPQlFmdDVmbHNBNjVLQUo5NkliczdyTmdhaUpZejNIUkJPQnJZaEZsNDR6OFpEa3p1WjNlQlVsSGZKTTdQMkI5YVZ4Q1VYbmZoSjNrQkQ1WENGSEQ4MHhIYVFhVHFZaUdDZy1teERWcnh5WVpvTF9IazBkXzdLNlNjY3pJbU5MVzQtaXI1VzQtLVk2SXZHUjhaajJKc2s1VjVoWUZheXdBZHIxSURWRm5Bb3VMWDl1c1hSbC1YcmJ4cGRIU0NkV1F2YWU5emwwQWs4NEgwaWdzMmZZdw?oc=5","date":"2021-01-26","type":"deal","source":"GlobeNewswire","summary":"BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc. - GlobeNewswire","headline":"BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOeHlPdnFhOWhrLVQzRFF6WHBkZU5zSzBtTUVUX1VBTlNlQ2ctYTdLbW1ISHllR0FneTllRDlrcHo0RzhVMS00RVB1WDVKdzctdjFzNDhCMFpobHVaQzRFRDZVbUc0Q2p5T3UtM0ZONkdsSmJzN0VMbTlyX3R5MV80ZG5lbFgwVDc5YXFuS1FVYmxXSDN3ejRxQUNRTXBtT0tW?oc=5","date":"2020-12-11","type":"pipeline","source":"Bloomberg.com","summary":"Glaxo Is Said to Bid $120 a Share for Eidos in Rival Offer - Bloomberg.com","headline":"Glaxo Is Said to Bid $120 a Share for Eidos in Rival Offer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxNelQwNDZCODJuUXdUeS1pNkRFdFBwbHJPOExmSEl3R2tJX0hDNzZJaVFnSXhRV2d0ZGpZNktzaE9sSm1rbG1DU2N0LV9zT2hQMFRZNDNHSWo5Snl6V1ZTMWlpYU8yX05ieTFGSmtUWmRIWmN2dklOVE9BdUUwRi1EcHMtUnpFenhUMnhHT0tnRm4tb0tDeXhyUi1pekpvZW5pcXNpUHkyN3ZqSUtTN0RoT1BIZXJNLThZekE3OHAwZ2tOLUs2LTkxTG9nT0pXNGRFMFR3?oc=5","date":"2020-10-05","type":"deal","source":"GlobeNewswire","summary":"BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement - GlobeNewswire","headline":"BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPLTBPQ2wwRm53MVk5elFDdGZxT0F4YW8wWmdpTnRoQjhvOFVka1p4eHFITEk1M1pycDdhQzZQa0xlVjZ4MzJGVjBjYzl0U3o5QnA1bFJOTmFhVUR4dk9QRHJsUkVjakRTbXlPYnJ6R3JsNVFZWFo0Z3pMdVZxcUFXVV96SFRPNk1GaUk4QVdsT0t3Nm5LcmhmZjVIVXV3MDVzSy1ZcXJDVmk?oc=5","date":"2020-10-05","type":"pipeline","source":"BioPharma Dive","summary":"With a sweetened offer, BridgeBio plans to reel in a subsidiary - BioPharma Dive","headline":"With a sweetened offer, BridgeBio plans to reel in a subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOVzU2WW5qYXRrUWhGQ3REQmlobng0eTNlZXYydC1mUldob09HSlJwTVR1NzNxbDIxOU9rN2hrcVVmVC14WWk5eWVIalpVOURRcThPWDZfaHJDb0J6dWZVTE5fOGwtcHdibEdXdEZldVcwWm12QU9BdzExVWw2T0IyWG02NWtNUF9RNVNLVE13Z0tmcVBJNk5xMDE3SlpLVm5XT0NqQ2dGM1hEOGFkSHZpSFl1ams3Q2N3?oc=5","date":"2020-06-24","type":"pipeline","source":"Fierce Pharma","summary":"Saunders finds life after Allergan on board at newly IPO'ed BridgeBio - Fierce Pharma","headline":"Saunders finds life after Allergan on board at newly IPO'ed BridgeBio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOLWhuWmhUTzdNNW81aHVSMTJHUHMzVGw5NEJhOURCWFhEYkUtYkwwc1ppRVd3ZjZTWGJ3UC15Sm5PaXN3c0Z6MF8xZFkzdWw1M0MyTzZzeHNaWGN1Q1o5V3k0NGNaaVRUck9pRzI0dm9hVEdLRGtxbmZWTERicDlKbVNaZUtSZm5TY01WRWZsdzVJN1NPb2xv?oc=5","date":"2019-10-14","type":"deal","source":"Fierce Biotech","summary":"BridgeBio scraps plan to buy Eidos after bids rebuffed - Fierce Biotech","headline":"BridgeBio scraps plan to buy Eidos after bids rebuffed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxOUkZVNG05ZVR2d2ZlVWdQYmdRUUU3QWl2S05NeHZld1ZkUkZPdkloZlhuZERnclRJcnFYc0hNTGdOMmZIZk0wWm1LMnppcTVvY0xNdVg1NFEzSVNLakpJbHRJcjhncEdPYXR0V0d4cXJsdGE5SmFVUVFfa1NyRXVOd1hnOUlxSHZYQzhoaEdpQ2FjUEdEam82enFJQ0o2cUxpYld6aDIxOA?oc=5","date":"2019-08-12","type":"deal","source":"The Business Journals","summary":"Little over year after IPO, biotech's majority owner wants to buy it all - The Business Journals","headline":"Little over year after IPO, biotech's majority owner wants to buy it all","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOYXBZbU9ERzBsRURabU1zdF9LdkMtaXk3bmwtYlpMRFdCVHpkTExmS2hiTWgtakdGYnlnalUydWUwWHY1YW5HbGFJVVNGMGlITXVqdHpjNzdfREducDFLMjBvbTdZYXkwX1lNNE96N0h3YTF1OVNVdzMyRFNRUmp5MEFCOWhaOW5sVlN6Y3pB?oc=5","date":"2019-01-23","type":"pipeline","source":"Fierce Biotech","summary":"KKR, Viking Global lead $299M round for BridgeBio - Fierce Biotech","headline":"KKR, Viking Global lead $299M round for BridgeBio","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}